C2C Stock Overview
Through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Concord Medical Services Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.25 |
| 52 Week High | US$36.00 |
| 52 Week Low | US$3.26 |
| Beta | -0.25 |
| 11 Month Change | 0% |
| 3 Month Change | -1.57% |
| 1 Year Change | -38.73% |
| 33 Year Change | -71.85% |
| 5 Year Change | -73.74% |
| Change since IPO | -89.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| C2C | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.02% |
| 1Y | -38.7% | 17.2% | 8.2% |
Return vs Industry: C2C underperformed the German Healthcare industry which returned 32.1% over the past year.
Return vs Market: C2C underperformed the German Market which returned 19.6% over the past year.
Price Volatility
| C2C volatility | |
|---|---|
| C2C Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C2C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine C2C's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 727 | Jianyu Yang | www.concordmedical.com |
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services.
Concord Medical Services Holdings Limited Fundamentals Summary
| C2C fundamental statistics | |
|---|---|
| Market cap | €30.81m |
| Earnings (TTM) | -€49.30m |
| Revenue (TTM) | €61.37m |
0.5x
P/S Ratio-0.6x
P/E RatioIs C2C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C2C income statement (TTM) | |
|---|---|
| Revenue | CN¥471.70m |
| Cost of Revenue | CN¥552.48m |
| Gross Profit | -CN¥80.78m |
| Other Expenses | CN¥298.15m |
| Earnings | -CN¥378.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -87.28 |
| Gross Margin | -17.13% |
| Net Profit Margin | -80.33% |
| Debt/Equity Ratio | 175.4% |
How did C2C perform over the long term?
See historical performance and comparison